

- Autofluorescence bronchoscopy, 1668
- Autoimmune autonomic ganglionopathy (AAG), 2642
- Autoimmune diseases, **377e-1**. *See also specific diseases*
- after HSCT, 139e-4
  - aging and, 94e-4
  - apoptosis protein defects and, 372e-27t, 377e-2
  - autoantigens associated with, 372e-23, 372e-24–25t
  - as cause of fever of unknown origin, 137t
  - cell- or organ-specific, 372e-24t
  - clinical features of, 377e-4, 377e-4t
  - cutaneous, **370**
  - cytokine defects and, 372e-27t
  - definition of, 372e-1
  - fever in, 126, 126t
  - genetic considerations in, 377e-3
  - in HIV infection, 1234
  - HLA molecule defects and, 372e-27t
  - immunopathogenesis of, 377e-3–4, 377e-3t, 377e-4t
  - immunotherapy for, 372e-30–31
  - mechanisms of, 377e-1–3, 377e-1t
  - molecular defects of immune system and, 372e-27t
  - myasthenia gravis and, 2703
  - organ-specific vs. systemic, 377e-4–5, 377e-5t
  - Sjögren's syndrome associated with, 2166, 2166t
  - systemic, 372e-24t
  - tissue damage in, 377e-3t, 377e-4
  - treatment of, 377e-5
  - types of, 377e-5t
  - in women, 6e-4
- Autoimmune encephalitis, 896
- Autoimmune hemolytic anemia, 377e-4, **658**
- Autoimmune hepatitis. *See* Hepatitis, autoimmune
- Autoimmune hypothyroidism, 2290–2292. *See also* Hypothyroidism
- Autoimmune lymphoproliferative syndrome (ALPS), 2112
- Autoimmune polyendocrine (polyglandular) syndrome-1 (APS-1)
- vs. APS-2, 2345t
  - autoantigens in, 372e-24t, 2345
  - clinical features of, 1343, 2113, 2323, 2324t, 2345, 2366
  - diagnosis of, 2345, 2346t
  - diseases associated with, 2344t, 2346t
  - etiology of, 2113, 2323
  - genetic considerations in, 377e-2, 2113, 2323, 2324t, 2345
  - treatment of, 2345
- Autoimmune polyendocrine (polyglandular) syndrome-2 (APS-2)
- vs. APS-1, 2345t
  - autoantigens in, 2347t
  - clinical features of, 2323, 2324t
  - diagnosis of, 2346–2347, 2346t
  - diseases associated with, 2344t, 2346, 2346t, 2347t
  - genetic considerations in, 2323, 2324t, 2346
  - treatment of, 2347
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). *See* Autoimmune polyendocrine (polyglandular) syndrome-1 (APS-1)
- Autoimmunity, **377e-1**
- cell- or organ-specific, 372e-24t
  - cytokine, 372e-25t
  - manifestations of, 377e-4, 377e-4t
  - mechanisms of, 372e-23, 377e-1–3, 377e-1t
  - paraneoplastic, 372e-25t
  - plasma protein, 372e-25t
  - prevention of, 377e-1, 377e-1t
  - primary immune deficiency diseases and, 2113
  - systemic, 372e-24t
- Autoinflammatory diseases. *See also specific diseases*
- definition of, 372e-1, 2212
  - fever in, 126, 126t
  - genetic considerations in, 372e-4, 372e-8t
  - hereditary, 2215
  - pyogenic arthritis, pyoderma gangrenosum, and acne syndrome, 372e-8t, 422, 2215
  - recurrent fever syndromes. *See* Hereditary recurrent fever syndromes
- Autolysins, 930
- Automated external defibrillation (AED), 1769
- Automaticity, cardiac, 273e-2–4
- Automatisms, 2543
- Autonomic dysfunction, **2637**
- approach to the patient, 2639–2641, 2640t
  - classification of, 2637–2638, 2638t
  - clinical features of, 2638–2639, 2639t
  - diagnosis of, 2640–2641, 2640t
  - drug-related, 2639, 2640t
  - syndromes of, **2641**
    - acute overactivity, 2643
    - in complex regional pain syndrome, 2643–2644
    - in diabetes mellitus, 2426, 2642
    - hereditary and sensory autonomic neuropathies, 2643
    - in hypoglycemia, 2432, 2432f
    - in multiple system atrophy, 2641. *See also* Multiple system atrophy (MSA)
    - orthostatic hypotension. *See* Orthostatic hypotension
    - paraneoplastic, 614t, 619
    - in peripheral nerve and neuromuscular junction disorders, 2642
    - postural orthostatic tachycardia syndrome, 1477, 2642–2643
    - primary hyperhidrosis, 2643
    - pure autonomic failure, 2642
    - with spinal cord lesions, 2641–2642
    - treatment of, 2644
- Autonomic dysreflexia, 2641–2642, 2660
- Autonomic nervous system
- anatomy of, 2637, 2637f
  - in blood pressure regulation, 1613
  - disorders of. *See* Autonomic dysfunction
  - normal activation of, 2638t
- Autonomic storm, 2643
- AutoPEEP, 1733, 1734f
- Autophagy
- in cancer cells, 102e-10, 103e-6
  - impaired, aging and, 94e-3
  - in microbial infection, 145e-7
  - in neurodegenerative diseases, 444e-9
- Autosomal dominant disorders, 436t, 437–438, 438f. *See also specific disorders*
- Autosomal dominant hypercholesterolemia, 2440t, 2442
- Autosomal dominant hypocalcemic hypercalciuria (ADHH), 2483
- Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), 2545t
- Autosomal dominant partial epilepsy with auditory features (ADPEAF), 2545t
- Autosomal recessive disorders, 436t, 437, 437f. *See also specific disorders*
- Autosomal recessive hypercholesterolemia, 2440t, 2442
- Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), 451e-3t
- Autosome, 426
- Availability heuristic, 19
- Avalon virus, 1308t
- Avanafil
- action of, 325f, 326f
  - adverse effects of, 328, 329t
  - characteristics of, 329t
  - contraindications to, 328, 329t
  - for erectile dysfunction, 328
- AV conduction block. *See* Atrioventricular (AV) conduction block
- Avian influenza A viruses, 145e-3, 784, 917, 1210
- AVM. *See* Arteriovenous malformation (AVM)
- Avobenzon, 391, 391t
- Avoidant/restrictive food intake disorder, 2719
- AVP. *See* Arginine vasopressin (AVP)
- AVP-NP11 gene, 2276
- Axial osteomalacia, 426e-6
- Axial spondyloarthritis, 2169, 2169t. *See also* Ankylosing spondylitis
- Axillofemoral bypass, 1645
- Axitinib
- action and targets of, 102e-5t, 102e-17, 103e-18t
  - adverse effects of, 103e-18t
  - for renal cell carcinoma, 102e-17, 579
- Ayurvedic medicine, 14e-1t
- 5-Azacytidine
- action of, 103e-20
  - adverse effects of, 103e-11t, 671
  - for AML, 683
  - for myelodysplasia, 671
- 5-Aza-2'-deoxycytidine, 102e-8, 102e-8f
- Azathioprine
- action of, 943, 1829t
  - adverse effects of, 103e-10t, 1829t, 1960, 2130t, 2132
    - bone marrow suppression, 1831, 1960
    - carcinogenicity, 477t
    - carcinoma, 1962
      - major, 2182t
    - neutropenia, 417
    - pancreatitis, 1960
    - prevention of, 2182
    - pure red cell aplasia, 668t
  - for autoimmune hepatitis, 2051–2052
  - for Behçet's syndrome, 2194
  - for bullous pemphigoid, 372
  - for cold agglutinin disease, 659
  - drug interactions of, 42t, 103e-10t, 1828, 2705
  - for epidermolysis bullosa acquisita, 374
  - genetic variations in response to, 39t, 40, 445
  - for granulomatosis with polyangiitis, 2185
  - for IBD, 1960
  - for idiopathic pulmonary fibrosis, 1712
  - for immunosuppression, 1828, 1829t
  - for inflammatory myopathies, 2201
  - for interstitial lung diseases, 1711, 1712
  - metabolism of, 34t, 103e-10t
  - for MS, 2672
  - for mucous membrane pemphigoid, 374
  - for myasthenia gravis, 2705
  - for neuromyelitis optica, 2673
  - for pemphigus vulgaris, 371
  - for photoallergy, 390
  - for reactive arthritis, 2175
  - for sarcoidosis, 2211, 2212t
  - for SLE, 2130t, 2132
  - for vasculitis, 2182
- Azelaic acid, 352
- Azelastine nasal spray, 2122
- AZF gene mutations, 439
- Azidothymidine. *See* Zidovudine (AZT)
- Azithromycin
- action of, 205e-8, 931, 931t, 943
  - adverse effects of, 246e-4t, 943
  - for *Babesia* infections, 780t, 1386–1387, 1386t
  - for bite-wound infections, 167e-2
  - for bronchiectasis prophylaxis, 1696
  - for *C. trachomatis* infections, 1171, 1172
  - for cat-scratch disease, 1081t
  - for chancroid, 880t, 1013
  - for cholera, 1064
  - for community-acquired pneumonia, 767t, 808t
  - for COPD exacerbation prophylaxis, 1706
  - for donovanosis, 198e-2, 198e-2t
  - drug interactions of, 246e-4t
  - for endemic treponematoses, 207e-2
  - for enteric fever, 1052t
  - for gonococcal infections, 1008, 1009t
  - indications for, 940t, 943
  - for infective endocarditis prophylaxis, 826t
  - for *Legionella* infections, 1020t
  - for leptospirosis, 1145t
  - for *M. pneumoniae* infections, 1164
  - for mucopurulent cervicitis, 876
  - for nontuberculous mycobacterial infections, 205e-8
  - for otitis media, 229t
  - for pertussis, 1024t
  - for pharyngitis, 232f, 233